Participant flow

Pomalidomide in Treating Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia · Source last updated 2025-09-04

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   2mg Pomolidomide per day per Cycle (Cycle = 28 days)

   id

   FG000

   title

   Cohort 2

2. description

   1mg Pomolidomide per day per Cycle (Cycle = 28 days)

   id

   FG001

   title

   Cohort 3

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         3

      2. group Id

         FG001

         num Subjects

         6

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         3

      2. group Id

         FG001

         num Subjects

         6

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         0

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

Six patients were screen failures; did not meet inclusion criteria. Original study design included Arms with assignment to increasing dose escalation including 3 and 4mg Pomolidomide Arms/Cohorts; however, safety concerns early on regarding Dose Limiting Toxicities for 2mg Cohort compelled omitting the 3 and 4mg Arms/Cohorts.

recruitment Details

Patient Eligibility:Waldenstrom relapsed,\>/18 - years old,ECOG \<\~2,Labs NCS,no prior cancers,females not preganant,\~1\> line(s) prior therapy, no therapy in 4 weeks. Excluded:pregnant, breast-feeding, serious diagnosis,chemotherapy reaction,prior pomalidomide,HIV/ Hepatitis A-C +,concurrent chemotherapy,grade\~\>2 neuropathy,andANC count \<\~1000K/ul.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice